Orchestra BioMed (OBIO)
Market Price (3/5/2026): $4.54 | Market Cap: $236.9 MilSector: Health Care | Industry: Biotechnology
Orchestra BioMed (OBIO)
Market Price (3/5/2026): $4.54Market Cap: $236.9 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -34% | Weak multi-year price returns2Y Excs Rtn is -64%, 3Y Excs Rtn is -127% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -75 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2670% |
| Megatrend and thematic driversMegatrends include Precision Medicine, Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Targeted Therapies, Show more. | Expensive valuation multiplesP/SPrice/Sales ratio is 84x | |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -13% | ||
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 430% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -2137%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -2157% | ||
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 161% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -36% | ||
| Key risksOBIO key risks include [1] failure to obtain regulatory approval for its Virtue® SAB and BackBeat CNT™ product candidates, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -34% |
| Megatrend and thematic driversMegatrends include Precision Medicine, Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -64%, 3Y Excs Rtn is -127% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -75 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2670% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 84x |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -13% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 430% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -2137%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -2157% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 161% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -36% |
| Key risksOBIO key risks include [1] failure to obtain regulatory approval for its Virtue® SAB and BackBeat CNT™ product candidates, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Q3 2025 Earnings Miss Impact.
Orchestra BioMed reported a Q3 2025 loss of $0.40 per share on November 10, 2025, missing analysts' consensus estimates of a loss of $0.38 per share. This negative earnings surprise, occurring just prior to the specified period, contributed to negative investor sentiment and selling pressure on the stock.
2. Termination of Terumo Strategic Agreement.
On October 24, 2025, Orchestra BioMed terminated its strategic distribution agreement with Terumo Corporation, which had previously generated $16.7 million in cumulative partnership revenues from 2019 through September 30, 2025. Although the company announced FDA Investigational Device Exemption (IDE) approval for the Virtue SAB U.S. pivotal trial and mediation with Terumo was ongoing, the termination of this revenue-generating partnership created uncertainty regarding future financial contributions and overall partnership stability.
Show more
Stock Movement Drivers
Fundamental Drivers
The -14.3% change in OBIO stock from 11/30/2025 to 3/4/2026 was primarily driven by a -14.3% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3042026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.32 | 4.56 | -14.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 3 | 0.0% |
| P/S Multiple | 98.5 | 84.4 | -14.3% |
| Shares Outstanding (Mil) | 52 | 52 | 0.0% |
| Cumulative Contribution | -14.3% |
Market Drivers
11/30/2025 to 3/4/2026| Return | Correlation | |
|---|---|---|
| OBIO | -14.3% | |
| Market (SPY) | 0.3% | 34.8% |
| Sector (XLV) | -0.4% | 24.6% |
Fundamental Drivers
The 67.0% change in OBIO stock from 8/31/2025 to 3/4/2026 was primarily driven by a 137.2% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 3042026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.73 | 4.56 | 67.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 3 | -4.3% |
| P/S Multiple | 35.6 | 84.4 | 137.2% |
| Shares Outstanding (Mil) | 38 | 52 | -26.4% |
| Cumulative Contribution | 67.0% |
Market Drivers
8/31/2025 to 3/4/2026| Return | Correlation | |
|---|---|---|
| OBIO | 67.0% | |
| Market (SPY) | 6.5% | 23.9% |
| Sector (XLV) | 14.8% | 27.4% |
Fundamental Drivers
The -2.8% change in OBIO stock from 2/28/2025 to 3/4/2026 was primarily driven by a -27.9% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282025 | 3042026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.69 | 4.56 | -2.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 3 | 6.5% |
| P/S Multiple | 66.7 | 84.4 | 26.7% |
| Shares Outstanding (Mil) | 38 | 52 | -27.9% |
| Cumulative Contribution | -2.8% |
Market Drivers
2/28/2025 to 3/4/2026| Return | Correlation | |
|---|---|---|
| OBIO | -2.8% | |
| Market (SPY) | 16.3% | 34.1% |
| Sector (XLV) | 6.9% | 28.9% |
Fundamental Drivers
The -51.2% change in OBIO stock from 2/28/2023 to 3/4/2026 was primarily driven by a -39.4% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282023 | 3042026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.35 | 4.56 | -51.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 3 | 0.0% |
| P/S Multiple | � | 84.4 | 0.0% |
| Shares Outstanding (Mil) | 32 | 52 | -39.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2023 to 3/4/2026| Return | Correlation | |
|---|---|---|
| OBIO | -51.2% | |
| Market (SPY) | 79.3% | 22.8% |
| Sector (XLV) | 29.2% | 17.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| OBIO Return | -21% | -1% | -9% | -56% | 4% | 5% | -66% |
| Peers Return | 20% | -19% | 10% | -8% | -5% | -12% | -18% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 81% |
Monthly Win Rates [3] | |||||||
| OBIO Win Rate | 33% | 67% | 50% | 33% | 33% | 33% | |
| Peers Win Rate | 54% | 44% | 52% | 60% | 52% | 27% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| OBIO Max Drawdown | -24% | -3% | -56% | -56% | -41% | -16% | |
| Peers Max Drawdown | -8% | -30% | -11% | -26% | -19% | -17% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MDT, BSX, ABT, EW, AMIX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/4/2026 (YTD)
How Low Can It Go
| Event | OBIO | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -80.1% | -25.4% |
| % Gain to Breakeven | 401.8% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -14.4% | -33.9% |
| % Gain to Breakeven | 16.8% | 51.3% |
| Time to Breakeven | 56 days | 148 days |
Compare to MDT, BSX, ABT, EW, AMIX
In The Past
Orchestra BioMed's stock fell -80.1% during the 2022 Inflation Shock from a high on 4/12/2023. A -80.1% loss requires a 401.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Orchestra BioMed (OBIO)
AI Analysis | Feedback
Here are 1-3 brief analogies for Orchestra BioMed (OBIO):
- Like Boston Scientific (a leader in cardiovascular devices) but also developing novel drugs for inflammatory diseases.
- Imagine a specialized version of Abbott Laboratories, concentrating on new cardiovascular devices and inflammatory drugs.
- A biotech company focused on cardiovascular and inflammatory diseases, similar in ambition to an early-stage Vertex Pharmaceuticals, but also including medical devices.
AI Analysis | Feedback
```html- Virtue® Sirolimus-Coated Balloon (SCB): A drug-coated balloon platform designed to deliver sirolimus to treat patients with coronary and peripheral artery disease.
- MODERATO® System: A neuromodulation system developed to treat patients with hypertension by modulating the sympathetic nervous system.
AI Analysis | Feedback
Orchestra BioMed (OBIO) operates primarily through strategic partnerships for the development and commercialization of its medical device technologies. In this business model, its major "customers" are larger medical technology companies that license, further develop, and globally distribute Orchestra BioMed's products. The company does not sell directly to individuals or healthcare providers.
Orchestra BioMed's major customers/partners include:
- Medtronic plc (Symbol: MDT)
- Terumo Corporation (Symbol: TSE: 4543)
AI Analysis | Feedback
null
AI Analysis | Feedback
```htmlDavid P. Hochman, Chairman, Chief Executive Officer and Founder
Mr. Hochman has served as Chairman and Chief Executive Officer of Orchestra BioMed since May 2018. From 2006 to 2019, he was Managing Partner of Orchestra Medical Ventures, an investment firm focused on creating high-impact medical device therapies. He also served as President of Accelerated Technologies, Inc., a medical device accelerator company now owned by Orchestra BioMed. Mr. Hochman has over 25 years of healthcare entrepreneurial, venture capital, and investment banking experience. He was a co-founder and board member of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) from 2013 to 2020. Prior to Orchestra Medical Ventures, he was Chief Executive Officer of Spencer Trask Edison Partners, LLC, an investment partnership focused on early-stage healthcare companies, and Managing Director of Spencer Trask Ventures, Inc., where he led financing transactions for over twenty early-stage companies. He also served as Chairman of the Board of Motus GI (NASDAQ: MOTS) from December 2016 to April 2023.
Andrew Taylor, Chief Financial Officer
Mr. Taylor joined Orchestra BioMed as Chief Financial Officer in June 2023. He brings over 20 years of CFO experience with emerging growth companies, with the last 15 years in the medical device sector. Prior to joining Orchestra BioMed, Mr. Taylor served as CFO of Motus GI Holdings, Inc. (NASDAQ: MOTS), where he helped lead the company's 2018 IPO. Before Motus GI, he spent 10 years as CFO and President of Avertix Medical, Inc. (f/k/a Angel Medical Systems, Inc.), where he remains a member of the Board of Directors.
Darren R. Sherman, President, Chief Operating Officer, Director and Founder
Mr. Sherman has served as President, Chief Operating Officer, and a member of the Board of Orchestra BioMed since May 2018. From 2009 until December 2019, Mr. Sherman served as Managing Partner of Orchestra Medical Ventures, an investment firm focused on creating high-impact medical device therapies. He co-founded Orchestra BioMed and its wholly-owned subsidiaries, Caliber, BackBeat, and Freehold.
William (Bill) Little, Executive Vice President of Corporate Development and Strategy
Mr. Little was appointed as Executive Vice President of Corporate Development and Strategy at Orchestra BioMed in June 2023. He most recently served as Chief Operating Officer at Neovasc, where he led its successful acquisition by Shockwave Medical in April 2023. Mr. Little has over 25 years of experience in the medical device industry, including leadership roles at Abbott Vascular, where he served as divisional vice president of Global Marketing.
Yuval Mika, Ph.D., General Manager and Chief Technology Officer, Bioelectronic Therapies
Dr. Mika has served as General Manager and Chief Technology Officer of Orchestra BioMed's Bioelectronic Therapies development group since May 2018. Since 2011, Dr. Mika served as the CEO of BackBeat Medical, LLC, which he co-founded. He led the development of BackBeat Cardiac Neuromodulation Therapy from concept and design through preclinical and clinical work. Dr. Mika has over 25 years of experience in the medical device industry, bringing technologies from concept to commercialization.
```AI Analysis | Feedback
The key risks to Orchestra BioMed (OBIO) primarily stem from the inherent challenges of developing and commercializing biomedical products.
- Risks related to regulatory approval of product candidates and ongoing regulation. As a biomedical company, Orchestra BioMed's success is heavily dependent on obtaining and maintaining regulatory approvals for its product candidates, such as Virtue® Sirolimus AngioInfusion™ Balloon (SAB) and BackBeat Cardiac Neuromodulation Therapy™ (CNT™). Delays, failures, or changes in regulatory requirements could significantly impede the company's ability to bring its products to market or sustain their commercialization.
- The timing of, and the company's ability to achieve expected regulatory and business milestones. This risk encompasses the successful and timely completion of clinical trials, such as the ongoing BACKBEAT global pivotal study, and other strategic objectives. Any setbacks in achieving these milestones, including issues with trial enrollment or results, could delay product launches, impact partnerships, and negatively affect the company's financial performance.
- The impact of competitive products and product candidates. Orchestra BioMed operates in a "very competitive and rapidly changing environment". The emergence of new or improved competitive products, or the failure of Orchestra BioMed's products to demonstrate superior efficacy or safety, could limit market adoption and profitability.
AI Analysis | Feedback
nullAI Analysis | Feedback
Orchestra BioMed (symbol: OBIO) is developing two main product candidates, Atrioventricular Interval Modulation (AVIM) Therapy and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB), which target substantial addressable markets globally.
For **AVIM Therapy**, also known as BackBeat Cardiac Neuromodulation Therapy (BackBeat CNT), designed for hypertensive pacemaker patients, Orchestra BioMed estimates an addressable market of over 750,000 patients worldwide annually. The company projects an annual global revenue opportunity for BackBeat CNT of over $5 billion. Another estimate indicates a revenue opportunity of $2 billion annually worldwide.
For the **Virtue Sirolimus AngioInfusion Balloon (Virtue SAB)**, which treats atherosclerotic artery disease including coronary in-stent restenosis (ISR), small vessel disease, and below-the-knee peripheral artery disease, Orchestra BioMed estimates a global market opportunity of over $4 billion annually. More broadly, the total global market opportunity for drug-eluting balloons is estimated to be over $10 billion annually. Specifically for coronary in-stent restenosis, an estimated 100,000 patients in the U.S. are affected annually, and worldwide, over 325,000 coronary ISR lesions may require treatment annually.
AI Analysis | Feedback
Orchestra BioMed (OBIO) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and strategic partnerships:
- Commercialization of BackBeat Cardiac Neuromodulation Therapy (AVIM therapy) for Hypertension: Orchestra BioMed has a strategic collaboration with Medtronic for the global development and commercialization of its BackBeat Cardiac Neuromodulation Therapy (AVIM therapy), designed to treat hypertension in pacemaker patients. The BACKBEAT global pivotal study initiated patient randomization in late 2023 / early 2024, and successful regulatory approval and subsequent commercialization by Medtronic will result in Orchestra BioMed sharing in the generated revenues.
- Commercialization of Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for Artery Disease: The company has a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB, a drug/device combination product candidate for the treatment of certain forms of artery disease. The Virtue SAB is anticipated to commence its pivotal U.S. IDE trial in the second half of 2025, with partnership revenues already contributing to the company's financials, indicating future growth potential upon broader commercialization.
- Expansion of Product Pipeline through Strategic Collaborations and Development: Orchestra BioMed's business model emphasizes expanding its product pipeline through acquisitions, strategic collaborations, licensing, and organic development. This continuous pursuit of new technologies and therapeutic candidates beyond its current flagship products is a foundational strategy for long-term revenue diversification and growth.
- Leveraging Strategic Partnerships with Leading Medical Device Companies: The company's core strategy revolves around forming risk-reward sharing partnerships with major medical device companies like Medtronic and Terumo. These collaborations are crucial for the global commercialization of Orchestra BioMed's technologies, allowing it to benefit from established commercial infrastructures and market reach, thereby driving significant revenue share without the extensive capital investment required for direct commercialization.
AI Analysis | Feedback
Share Issuance
- In August 2025, Orchestra BioMed priced an underwritten public offering of 9,413,637 shares of common stock at $2.75 per share and pre-funded warrants for 5,136,363 shares at $2.7499 per warrant, expecting approximately $40 million in gross proceeds.
- As part of strategic transactions and concurrent offerings in August 2025, Medtronic purchased 4,077,427 shares and Ligand purchased 1,818,181 shares in a private placement, each at $2.75 per share.
- In November 2025, Orchestra BioMed filed a prospectus for the potential sale of approximately 8.03 million shares by selling stockholders, including 4.21 million shares for Covidien Group and 1.81 million shares for Ligand Pharmaceuticals via a private placement, with no proceeds going to the company from these specific sales.
Inbound Investments
- In July 2025, Orchestra BioMed secured $70 million in new capital from Ligand Pharmaceuticals ($40 million) and Medtronic ($30 million) to advance its late-stage partnered cardiology programs.
- In August 2025, the company secured over $111 million in gross proceeds and committed capital, comprising $56.2 million from completed equity offerings and $55 million in royalty-based, non-dilutive investments from Medtronic and Ligand.
- In July 2022, Orchestra BioMed completed a $110 million Series D private equity financing, which included investments from Medtronic, RTW Investments, Perceptive Advisors, and Terumo Corporation.
Outbound Investments
- Orchestra BioMed has one recorded investment in Vivasure Medical.
- As of recent reports, Orchestra BioMed has not made any acquisitions.
Capital Expenditures
- Net cash utilized for the purchase of fixed assets amounted to $15.6 million during the second quarter of 2025, primarily due to increased research and development costs.
- Research and development expenses, which support product development, increased to $13.5 million in Q1 2025 and $13.9 million in Q2 2025, largely driven by the ongoing BACKBEAT global pivotal study.
- Proceeds from the August 2025 public offering and related financings are intended to fund key programs, including the AVIM therapy program, the BACKBEAT study, and the Virtue Sirolimus AngioInfusion Balloon (SAB) program and trial.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Is Orchestra BioMed Stock Built to Withstand More Downside? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to OBIO.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 78.72 |
| Mkt Cap | 78.5 |
| Rev LTM | 12,979 |
| Op Inc LTM | 2,795 |
| FCF LTM | 2,102 |
| FCF 3Y Avg | 2,491 |
| CFO LTM | 2,775 |
| CFO 3Y Avg | 3,491 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.9% |
| Rev Chg 3Y Avg | 4.7% |
| Rev Chg Q | 8.7% |
| QoQ Delta Rev Chg LTM | 2.1% |
| Op Mgn LTM | 18.6% |
| Op Mgn 3Y Avg | 18.2% |
| QoQ Delta Op Mgn LTM | -0.4% |
| CFO/Rev LTM | 20.5% |
| CFO/Rev 3Y Avg | 20.0% |
| FCF/Rev LTM | 15.2% |
| FCF/Rev 3Y Avg | 14.3% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 78.5 |
| P/S | 5.3 |
| P/EBIT | 20.7 |
| P/E | 28.4 |
| P/CFO | 18.7 |
| Total Yield | 2.7% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 2.1% |
| D/E | 0.1 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 1.9% |
| 3M Rtn | -7.7% |
| 6M Rtn | -4.3% |
| 12M Rtn | -5.1% |
| 3Y Rtn | 9.4% |
| 1M Excs Rtn | 3.4% |
| 3M Excs Rtn | -10.7% |
| 6M Excs Rtn | -11.7% |
| 12M Excs Rtn | -24.1% |
| 3Y Excs Rtn | -57.3% |
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 |
|---|---|---|
| Development of clinical and preclinical product candidates through risk-reward sharing partnerships | 3 | |
| Partnership revenue | 3 | |
| Product revenue | 1 | |
| Total | 3 | 4 |
| $ Mil | 2024 | 2023 |
|---|---|---|
| Development of clinical and preclinical product candidates through risk-reward sharing partnerships | -49 | |
| Total | -49 |
Price Behavior
| Market Price | $4.56 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 08/04/2020 | |
| Distance from 52W High | -14.8% | |
| 50 Days | 200 Days | |
| DMA Price | $4.17 | $3.50 |
| DMA Trend | up | down |
| Distance from DMA | 9.3% | 30.2% |
| 3M | 1YR | |
| Volatility | 69.3% | 87.4% |
| Downside Capture | 254.91 | 245.52 |
| Upside Capture | 213.12 | 210.41 |
| Correlation (SPY) | 34.3% | 33.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.00 | 2.16 | 2.32 | 1.55 | 1.55 | 1.67 |
| Up Beta | 1.93 | 3.00 | 4.72 | 3.29 | 0.75 | 0.98 |
| Down Beta | 0.55 | 0.94 | 0.81 | -0.70 | 1.68 | 1.76 |
| Up Capture | 584% | 297% | 179% | 365% | 392% | 624% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 12 | 22 | 28 | 64 | 127 | 362 |
| Down Capture | 253% | 213% | 262% | 149% | 155% | 113% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 9 | 19 | 32 | 58 | 118 | 376 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OBIO | |
|---|---|---|---|---|
| OBIO | 10.9% | 87.5% | 0.51 | - |
| Sector ETF (XLV) | 6.4% | 17.4% | 0.20 | 29.6% |
| Equity (SPY) | 18.5% | 19.2% | 0.76 | 33.2% |
| Gold (GLD) | 78.4% | 26.1% | 2.20 | 8.5% |
| Commodities (DBC) | 19.7% | 17.1% | 0.89 | 6.2% |
| Real Estate (VNQ) | 5.3% | 16.6% | 0.14 | 18.6% |
| Bitcoin (BTCUSD) | -20.7% | 45.1% | -0.38 | 17.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OBIO | |
|---|---|---|---|---|
| OBIO | -20.0% | 90.8% | 0.13 | - |
| Sector ETF (XLV) | 8.3% | 14.5% | 0.39 | 14.4% |
| Equity (SPY) | 13.9% | 17.0% | 0.65 | 17.6% |
| Gold (GLD) | 23.4% | 17.3% | 1.11 | 7.4% |
| Commodities (DBC) | 11.2% | 19.0% | 0.47 | 5.6% |
| Real Estate (VNQ) | 5.2% | 18.8% | 0.18 | 13.3% |
| Bitcoin (BTCUSD) | 7.7% | 56.8% | 0.36 | 9.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OBIO | |
|---|---|---|---|---|
| OBIO | -9.4% | 86.7% | 0.16 | - |
| Sector ETF (XLV) | 10.8% | 16.5% | 0.54 | 13.7% |
| Equity (SPY) | 15.4% | 17.9% | 0.74 | 17.0% |
| Gold (GLD) | 15.0% | 15.6% | 0.80 | 8.2% |
| Commodities (DBC) | 9.0% | 17.6% | 0.42 | 5.8% |
| Real Estate (VNQ) | 6.5% | 20.7% | 0.28 | 12.9% |
| Bitcoin (BTCUSD) | 66.2% | 66.8% | 1.06 | 10.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/12/2024 | 10-Q |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 03/27/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 06/30/2022 | 10/24/2022 | S-4/A |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hochman, David P | See Remarks | Direct | Buy | 11172025 | 4.07 | 5,000 | 20,350 | 2,494,186 | Form |
| 2 | Aryeh, Jason | Direct | Buy | 9192025 | 2.45 | 1,000 | 2,450 | 265,781 | Form | |
| 3 | Fain, Eric S | the Fain Living Trust | Buy | 8252025 | 2.61 | 5,760 | 15,034 | 187,160 | Form | |
| 4 | Sherman, Darren | See Remarks | Direct | Buy | 8252025 | 2.62 | 3,000 | 7,860 | 2,428,313 | Form |
| 5 | Hochman, David P | See Remarks | Direct | Buy | 8252025 | 2.49 | 6,000 | 14,940 | 1,622,135 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.